Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 25;11(5):e045559.
doi: 10.1136/bmjopen-2020-045559.

Efficacy and safety of butylphthalide for patients who had acute ischaemic stroke receiving intravenous thrombolysis or endovascular treatment (BAST trial): study protocol for a randomised placebo-controlled trial

Xuelei Zhang  1   2   3 , Anxin Wang  2   4 , Jing Yu Zhang  1   2 , Baixue Jia  1   2 , Xiaochuan Huo  1   2 , Yingting Zuo  5 , Xue Tian  5 , Yilong Wang  6   4 , Zhongrong Miao  7   2 ; BAST study investigators
Affiliations

Efficacy and safety of butylphthalide for patients who had acute ischaemic stroke receiving intravenous thrombolysis or endovascular treatment (BAST trial): study protocol for a randomised placebo-controlled trial

Xuelei Zhang et al. BMJ Open. .

Abstract

Introduction: As a neuroprotective medication, butylphthalide (NBP) may help protect against cerebral ischaemic injury. However, evidence on whether NBP influences the outcomes of patients who had acute ischaemic stroke who are receiving revascularisation treatment is limited. This study aims to evaluate whether additional NBP therapy can improve the functional outcome of patients who receive intravenous recombinant tissue plasminogen activator and/or endovascular treatment (EVT).

Methods and analysis: The study will be a randomised, double-blind, placebo-controlled, multiple-centre, parallel group trial. The sample size is estimated at 1200 patients. Eligible patients will be randomised at a 1:1 ratio to receive either NBP or placebo daily for 90 days, which will include 14 days of injections and 76 days of capsules. The first use of NBP/placebo will be started within 6 hours of onset of ischaemic stroke. The primary outcome is the functional outcome as assessed by the 90-day modified Rankin Scale, adjusted for baseline scores on the National Institutes of Health Stroke Scale. The primary safety outcome is the percentage of serious adverse events during the 90 days of treatment. This trial will determine whether NBP medication benefits patients who had acute ischaemic stroke who receive intravenous thrombolysis or EVT.

Ethics and dissemination: The protocol was written according to the general ethical guidelines of the Declaration of Helsinki and approved by the Institutional Review Board/Ethics Committee of Beijing Tiantan Hospital, Capital Medical University with approval number KY 2018-003-02. Ethics committees of all participating sites have approved the study . Results of the study will be published in peer-reviewed scientific journals and shared in scientific presentations.

Trial registration number: NCT03539445.

Keywords: stroke; stroke medicine; vascular medicine.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Yang G, Wang Y, Zeng Y, et al. . Rapid health transition in China, 1990–2010: findings from the global burden of disease study 2010. Lancet 2013;381:1987–2015. 10.1016/S0140-6736(13)61097-1 - DOI - PMC - PubMed
    1. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. . Global and regional burden of stroke during 1990-2010: findings from the global burden of disease study 2010. Lancet 2014;383:245–55. 10.1016/S0140-6736(13)61953-4 - DOI - PMC - PubMed
    1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group . Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–8. 10.1056/NEJM199512143332401 - DOI - PubMed
    1. Hacke W, Donnan G, Fieschi C, et al. . Association of outcome with early stroke treatment: pooled analysis of Atlantis, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768–74. 10.1016/S0140-6736(04)15692-4 - DOI - PubMed
    1. Wahlgren N, Ahmed N, Dávalos A, et al. . Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in Stroke-Monitoring study (SITS-MOST): an observational study. Lancet 2007;369:275–82. 10.1016/S0140-6736(07)60149-4 - DOI - PubMed

Publication types

Associated data